Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Sponsor: Ascletis Pharma (China) Co., Limited
Summary
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.
Official title: A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Type 2 Diabetes Mellitus (AURORA-2)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1560
Start Date
2026-08-28
Completion Date
2028-07
Last Updated
2026-09-16
Healthy Volunteers
No
Interventions
ASC30 tablets A1
ASC30 tablets A1 administered orally once daily.
Placebo
Matching placebo tablets administered orally once daily.
Locations (135)
AURORA-2 Clinical Site
Birmingham, Alabama, United States
AURORA-2 Clinical Site
Huntsville, Alabama, United States
AURORA-2 Clinical Site
Peoria, Arizona, United States
AURORA-2 Clinical Site
Phoenix, Arizona, United States
AURORA-2 Clinical Site
Tucson, Arizona, United States
AURORA-2 Clinical Site
Little Rock, Arkansas, United States
AURORA-2 Clinical Site
Banning, California, United States
AURORA-2 Clinical Site
Chula Vista, California, United States
AURORA-2 Clinical Site
Covina, California, United States
AURORA-2 Clinical Site
Gardena, California, United States
AURORA-2 Clinical Site
La Mesa, California, United States
AURORA-2 Clinical Site
Los Angeles, California, United States
AURORA-2 Clinical Site
Sacramento, California, United States
AURORA-2 Clinical Site
Tarzana, California, United States
AURORA-2 Clinical Site
Tustin, California, United States
AURORA-2 Clinical Site
Washington D.C., District of Columbia, United States
AURORA-2 Clinical Site
Boca Raton, Florida, United States
AURORA-2 Clinical Site
Daytona Beach, Florida, United States
AURORA-2 Clinical Site
Jacksonville, Florida, United States
AURORA-2 Clinical Site
Leesburg, Florida, United States
AURORA-2 Clinical Site
Melbourne, Florida, United States
AURORA-2 Clinical Site
South Miami, Florida, United States
AURORA-2 Clinical Site
Tampa, Florida, United States
AURORA-2 Clinical Site
The Villages, Florida, United States
AURORA-2 Clinical Site
Winter Park, Florida, United States
AURORA-2 Clinical Site
Canton, Georgia, United States
AURORA-2 Clinical Site
Decatur, Georgia, United States
AURORA-2 Clinical Site
Union City, Georgia, United States
AURORA-2 Clinical Site
Boise, Idaho, United States
AURORA-2 Clinical Site
Schaumburg, Illinois, United States
AURORA-2 Clinical Site
Evansville, Indiana, United States
AURORA-2 Clinical Site
Indianapolis, Indiana, United States
AURORA-2 Clinical Site
Valparaiso, Indiana, United States
AURORA-2 Clinical Site
Kansas City, Kansas, United States
AURORA-2 Clinical Site
Baton Rouge, Louisiana, United States
AURORA-2 Clinical Site
Metairie, Louisiana, United States
AURORA-2 Clinical Site
Bowie, Maryland, United States
AURORA-2 Clinical Site
Rockville, Maryland, United States
AURORA-2 Clinical Site
Southfield, Michigan, United States
AURORA-2 Clinical Site
Mankato, Minnesota, United States
AURORA-2 Clinical Site
Gulfport, Mississippi, United States
AURORA-2 Clinical Site
Jackson, Mississippi, United States
AURORA-2 Clinical Site
Olive Branch, Mississippi, United States
AURORA-2 Clinical Site
Columbia, Missouri, United States
AURORA-2 Clinical Site
St Louis, Missouri, United States
AURORA-2 Clinical Site
Las Vegas, Nevada, United States
AURORA-2 Clinical Site
Jersey City, New Jersey, United States
AURORA-2 Clinical Site
East Northport, New York, United States
AURORA-2 Clinical Site
East Syracuse, New York, United States
AURORA-2 Clinical Site
New Windsor, New York, United States
AURORA-2 Clinical Site
Charlotte, North Carolina, United States
AURORA-2 Clinical Site
Durham, North Carolina, United States
AURORA-2 Clinical Site
Greenville, North Carolina, United States
AURORA-2 Clinical Site
Morehead City, North Carolina, United States
AURORA-2 Clinical Site
Raleigh, North Carolina, United States
AURORA-2 Clinical Site
Cincinnati, Ohio, United States
AURORA-2 Clinical Site
Cleveland, Ohio, United States
AURORA-2 Clinical Site
Columbus, Ohio, United States
AURORA-2 Clinical Site
Dayton, Ohio, United States
AURORA-2 Clinical Site
Oklahoma City, Oklahoma, United States
AURORA-2 Clinical Site
Eugene, Oregon, United States
AURORA-2 Clinical Site
Philadelphia, Pennsylvania, United States
AURORA-2 Clinical Site
Pittsburgh, Pennsylvania, United States
AURORA-2 Clinical Site
Bluffton, South Carolina, United States
AURORA-2 Clinical Site
Clemson, South Carolina, United States
AURORA-2 Clinical Site
Columbia, South Carolina, United States
AURORA-2 Clinical Site
Gaffney, South Carolina, United States
AURORA-2 Clinical Site
Memphis, Tennessee, United States
AURORA-2 Clinical Site
Austin, Texas, United States
AURORA-2 Clinical Site
Brownsville, Texas, United States
AURORA-2 Clinical Site
DeSoto, Texas, United States
AURORA-2 Clinical Site
Frisco, Texas, United States
AURORA-2 Clinical Site
Houston, Texas, United States
AURORA-2 Clinical Site
Mesquite, Texas, United States
AURORA-2 Clinical Site
San Antonio, Texas, United States
AURORA-2 Clinical Site
San Antonio, Texas, United States
AURORA-2 Clinical Site
Sugar Land, Texas, United States
AURORA-2 Clinical Site
Tomball, Texas, United States
AURORA-2 Clinical Site
Waxahachie, Texas, United States
AURORA-2 Clinical Site
Weslaco, Texas, United States
AURORA-2 Clinical Site
Wichita Falls, Texas, United States
AURORA-2 Clinical Site
Salt Lake City, Utah, United States
AURORA-2 Clinical Site
Hampton, Virginia, United States
AURORA-2 Clinical Site
Seattle, Washington, United States
AURORA-2 Clinical Site
Pardubice, Czechia
AURORA-2 Clinical Site
Prague, Czechia
AURORA-2 Clinical Site
Prague, Czechia
AURORA-2 Clinical Site
Uherské Hradiště, Czechia
AURORA-2 Clinical Site
Berlin, Germany
AURORA-2 Clinical Site
Berlin, Germany
AURORA-2 Clinical Site
Essen, Germany
AURORA-2 Clinical Site
Hanover, Germany
AURORA-2 Clinical Site
Athens, Greece
AURORA-2 Clinical Site
Athens, Greece
AURORA-2 Clinical Site
Athens, Greece
AURORA-2 Clinical Site
Larissa, Greece
AURORA-2 Clinical Site
Marousi, Greece
AURORA-2 Clinical Site
Palaió Fáliro, Greece
AURORA-2 Clinical Site
Pylaia, Greece
AURORA-2 Clinical Site
Thessaloniki, Greece
AURORA-2 Clinical Site
Thessaloniki, Greece
AURORA-2 Clinical Site
Biała Podlaska, Poland
AURORA-2 Clinical Site
Bydgoszcz, Poland
AURORA-2 Clinical Site
Częstochowa, Poland
AURORA-2 Clinical Site
Gdansk, Poland
AURORA-2 Clinical Site
Gdynia, Poland
AURORA-2 Clinical Site
Gdynia, Poland
AURORA-2 Clinical Site
Katowice, Poland
AURORA-2 Clinical Site
Krakow, Poland
AURORA-2 Clinical Site
Krakow, Poland
AURORA-2 Clinical Site
Lodz, Poland
AURORA-2 Clinical Site
Lodz, Poland
AURORA-2 Clinical Site
Lublin, Poland
AURORA-2 Clinical Site
Lublin, Poland
AURORA-2 Clinical Site
Poznan, Poland
AURORA-2 Clinical Site
Poznan, Poland
AURORA-2 Clinical Site
Puławy, Poland
AURORA-2 Clinical Site
Siedlce, Poland
AURORA-2 Clinical Site
Staszów, Poland
AURORA-2 Clinical Site
Torun, Poland
AURORA-2 Clinical Site
Warsaw, Poland
AURORA-2 Clinical Site
Warsaw, Poland
AURORA-2 Clinical Site
Warsaw, Poland
AURORA-2 Clinical Site
Warsaw, Poland
AURORA-2 Clinical Site
Warsaw, Poland
AURORA-2 Clinical Site
Wroclaw, Poland
AURORA-2 Clinical Site
Wroclaw, Poland
AURORA-2 Clinical Site
Cardiff, United Kingdom
AURORA-2 Clinical Site
Edgbaston, United Kingdom
AURORA-2 Clinical Site
Glasgow, United Kingdom
AURORA-2 Clinical Site
London, United Kingdom
AURORA-2 Clinical Site
Manchester, United Kingdom
AURORA-2 Clinical Site
Manchester, United Kingdom
AURORA-2 Clinical Site
Stoke-on-Trent, United Kingdom
AURORA-2 Clinical Site
Warrington, United Kingdom